{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:58:35Z","timestamp":1794110315349,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI131430"],"award-info":[{"award-number":["R01AI131430"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI073146"],"award-info":[{"award-number":["R01AI073146"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI096138"],"award-info":[{"award-number":["R01AI096138"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Here we report an ultra-long-acting tunable, biodegradable, and removable polymer-based delivery system that offers sustained drug delivery for up to one year for HIV treatment or prophylaxis. This robust formulation offers the ability to integrate multiple drugs in a single injection, which is particularly important to address the potential for drug resistance with monotherapy. Six antiretroviral drugs were selected based on their solubility in\n                    <jats:italic>N<\/jats:italic>\n                    -methyl-2-pyrrolidone and relevance as a combination therapy for HIV treatment or prevention. All drugs released with concentrations above their protein-adjusted inhibitory concentration and retained their physical and chemical properties within the formulation and upon release. The versatility of this formulation to integrate multiple drugs and provide sustained plasma concentrations from several weeks to up to one year, combined with its ability to be removed to terminate the treatment if necessary, makes it attractive as a drug delivery platform technology for a wide range of applications.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-12141-5","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T06:15:48Z","timestamp":1568960148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["Ultra-long-acting tunable biodegradable and removable controlled release implants for drug delivery"],"prefix":"10.1038","volume":"10","author":[{"given":"S. Rahima","family":"Benhabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kovarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-6978","authenticated-orcid":false,"given":"Daijha J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopali","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phong T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie L.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anush","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha M.","family":"Fix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-1478","authenticated-orcid":false,"given":"Orrin","family":"Thayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria J.","family":"Hazuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Dayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Mumper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D. M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-0482","authenticated-orcid":false,"given":"J.","family":"Victor Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"12141_CR1","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1021\/jacs.6b01784","volume":"138","author":"CC Huang","year":"2016","unstructured":"Huang, C. C. et al. An implantable depot that can generate oxygen in situ for overcoming hypoxia-induced resistance to anticancer drugs in chemotherapy. J. Am. Chem. Soc. 138, 5222\u20135225 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"12141_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jconrel.2015.02.019","volume":"203","author":"LS Karfeld-Sulzer","year":"2015","unstructured":"Karfeld-Sulzer, L. S. et al. N-methyl pyrrolidone\/bone morphogenetic protein-2 double delivery with in situ forming implants. J. Control Release 203, 181\u2013188 (2015).","journal-title":"J. Control Release"},{"key":"12141_CR3","doi-asserted-by":"publisher","first-page":"15078","DOI":"10.1021\/jacs.6b09770","volume":"138","author":"G Pan","year":"2016","unstructured":"Pan, G. et al. Biomimetic design of mussel-derived bioactive peptides for dual-functionalization of titanium-based biomaterials. J. Am. Chem. Soc. 138, 15078\u201315086 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"12141_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","volume":"172","author":"M Parent","year":"2013","unstructured":"Parent, M. et al. PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release. J. Control Release 172, 292\u2013304 (2013).","journal-title":"J. Control Release"},{"key":"12141_CR5","doi-asserted-by":"publisher","first-page":"17840","DOI":"10.1021\/ja106288c","volume":"132","author":"SY Wong","year":"2010","unstructured":"Wong, S. Y. et al. Dual functional polyelectrolyte multilayer coatings for implants: permanent microbicidal base with controlled release of therapeutic agents. J. Am. Chem. Soc. 132, 17840\u201317848 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"12141_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijpharm.2012.01.005","volume":"426","author":"DN Kapoor","year":"2012","unstructured":"Kapoor, D. N., Katare, O. P. & Dhawan, S. In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor. Int J. Pharm. 426, 132\u2013143 (2012).","journal-title":"Int J. Pharm."},{"key":"12141_CR7","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1039\/C6NR07858C","volume":"9","author":"AR Town","year":"2017","unstructured":"Town, A. R. et al. Dual-stimuli responsive injectable microgel\/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. Nanoscale 9, 6302\u20136314 (2017).","journal-title":"Nanoscale"},{"key":"12141_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.drudis.2013.01.013","volume":"18","author":"P Agarwal","year":"2013","unstructured":"Agarwal, P. & Rupenthal, I. D. Injectable implants for the sustained release of protein and peptide drugs. Drug Disco. Today 18, 337\u2013349 (2013).","journal-title":"Drug Disco. Today"},{"key":"12141_CR9","unstructured":"Durect (2006)."},{"key":"12141_CR10","first-page":"74","volume":"1","author":"K Malik","year":"2010","unstructured":"Malik, K., Singh, I., Nagpal, M. & Arora, S. Atrigel: A potential parenteral controlled drug delivery system. Der Pharm. Sin. 1, 74\u201381 (2010).","journal-title":"Der Pharm. Sin."},{"key":"12141_CR11","doi-asserted-by":"crossref","unstructured":"Rathbone, M. J. & McDowell, A. Long Acting Animal Health Drug Products: Fundamentals and Applications (Springer, 2013).","DOI":"10.1007\/978-1-4614-4439-8"},{"key":"12141_CR12","unstructured":"Indivior PLC, FDA Approves SUBLOCADETM (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder http:\/\/www.indivior.com\/investor-news\/fda-approves-sublocade-buprenorphine-extended-release-first-monthly-injectable-buprenorphine-formulation-treat-moderate-severe-opioid-use-disorder\/\u00a0(2018)."},{"key":"12141_CR13","unstructured":"Indivior PLC, PERSERIS\u2014a once-monthly, risperidone-containing long-acting injectable (LAI)\u00a0https:\/\/www.perserishcp.com\/."},{"key":"12141_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jconrel.2012.04.016","volume":"161","author":"S Kempe","year":"2012","unstructured":"Kempe, S. & Mader, K. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J. Control. Release 161, 668\u2013679 (2012).","journal-title":"J. Control. Release"},{"key":"12141_CR15","doi-asserted-by":"crossref","unstructured":"Wright, J. C. & Burgess, D. J. Long acting injections and implants (Springer, 2011).","DOI":"10.1007\/978-1-4614-0554-2"},{"key":"12141_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/187221107779814113","volume":"1","author":"K Al-Tahami","year":"2007","unstructured":"Al-Tahami, K. & Singh, J. Smart polymer based delivery systems for peptides and proteins. Recent Pat. Drug Deliv. Formul. 1, 65\u201371 (2007).","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"12141_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/(SICI)1097-4636(20000605)50:3<388::AID-JBM13>3.0.CO;2-F","volume":"50","author":"RE Eliaz","year":"2000","unstructured":"Eliaz, R. E. & Kost, J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J. Biomed. Mater. Res. 50, 388\u2013396 (2000).","journal-title":"J. Biomed. Mater. Res."},{"key":"12141_CR18","doi-asserted-by":"crossref","unstructured":"Dunn, R. L. in Modified-Release Drug Delivery Technology, 647\u2013655 (Informa Healthcare, 2002).","DOI":"10.1201\/9780203910337.ch54"},{"key":"12141_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2013.12.020","volume":"176","author":"RR Thakur","year":"2014","unstructured":"Thakur, R. R., McMillan, H. L. & Jones, D. S. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J. Control. Release 176, 8\u201323 (2014).","journal-title":"J. Control. Release"},{"key":"12141_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.18433\/J3P306","volume":"13","author":"A Jouyban","year":"2010","unstructured":"Jouyban, A., Fakhree, M. A. & Shayanfar, A. Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J. Pharm. Pharm. Sci. 13, 524\u2013535 (2010).","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"12141_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/00498254.2013.845706","volume":"44","author":"Evan A. Thackaberry","year":"2013","unstructured":"Thackaberry, E. A. et al. Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits. Xenobiotica. 44, 235\u2013241 (2013).","journal-title":"Xenobiotica"},{"key":"12141_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/toxsci\/kfp264","volume":"113","author":"TS Poet","year":"2010","unstructured":"Poet, T. S. et al. Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling. Toxicol. Sci. 113, 468\u2013482 (2010).","journal-title":"Toxicol. Sci."},{"key":"12141_CR23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia, H. K. & Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polym. (Basel) 3, 1377\u20131397 (2011).","journal-title":"Polym. (Basel)"},{"key":"12141_CR24","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.7150\/thno.4181","volume":"2","author":"L Solorio","year":"2012","unstructured":"Solorio, L. et al. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging. Theranostics 2, 1064\u20131077 (2012).","journal-title":"Theranostics"},{"key":"12141_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jconrel.2005.09.038","volume":"109","author":"AJ McHugh","year":"2005","unstructured":"McHugh, A. J. The role of polymer membrane formation in sustained release drug delivery systems. J. Control Release 109, 211\u2013221 (2005).","journal-title":"J. Control Release"},{"key":"12141_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/jps.21415","volume":"98","author":"R Astaneh","year":"2009","unstructured":"Astaneh, R., Erfan, M., Moghimi, H. & Mobedi, H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J. Pharm. Sci. 98, 135\u2013145 (2009).","journal-title":"J. Pharm. Sci."},{"key":"12141_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0168-3659(99)00159-5","volume":"62","author":"KJ Brodbeck","year":"1999","unstructured":"Brodbeck, K. J., DesNoyer, J. R. & McHugh, A. J. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J. Control Release 62, 333\u2013344 (1999).","journal-title":"J. Control Release"},{"key":"12141_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-3659(98)00158-8","volume":"58","author":"PD Graham","year":"1999","unstructured":"Graham, P. D., Brodbeck, K. J. & McHugh, A. J. Phase inversion dynamics of PLGA solutions related to drug delivery. J. Control Release 58, 233\u2013245 (1999).","journal-title":"J. Control Release"},{"key":"12141_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10717540590968873","volume":"12","author":"S Prabhu","year":"2005","unstructured":"Prabhu, S., Tran, L. P. & Betageri, G. V. Effect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implants. Drug Deliv. 12, 393\u2013398 (2005).","journal-title":"Drug Deliv."},{"key":"12141_CR30","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1002\/app.27520","volume":"107","author":"M Zare","year":"2008","unstructured":"Zare, M. et al. Effect of additives on release profile of leuprolide acetate in an in situ forming controlled-release system: In vitro study. J. Appl Polym. Sci. 107, 3781\u20133787 (2008).","journal-title":"J. Appl Polym. Sci."},{"key":"12141_CR31","doi-asserted-by":"publisher","first-page":"9210","DOI":"10.1128\/JVI.01164-10","volume":"84","author":"T Bar-Magen","year":"2010","unstructured":"Bar-Magen, T. et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84, 9210\u20139216 (2010).","journal-title":"J. Virol."},{"key":"12141_CR32","doi-asserted-by":"publisher","first-page":"8154","DOI":"10.1021\/acs.jmedchem.5b01037","volume":"58","author":"IT Raheem","year":"2015","unstructured":"Raheem, I. T. et al. Discovery of 2-pyridinone aminals: a prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors. J. Med Chem. 58, 8154\u20138165 (2015).","journal-title":"J. Med Chem."},{"key":"12141_CR33","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acs.jmedchem.5b01957","volume":"59","author":"IT Raheem","year":"2016","unstructured":"Raheem, I. T. et al. Correction to discovery of 2-pyridinone aminals: a prodrug strategy to advance a second generation of HIV-1 integrase strand transfer inhibitors. J. Med Chem. 59, 486 (2016).","journal-title":"J. Med Chem."},{"key":"12141_CR34","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbm.b.31243","volume":"89","author":"L Nikkola","year":"2009","unstructured":"Nikkola, L., Viitanen, P. & Ashammakhi, N. Temporal control of drug release from biodegradable polymer: multicomponent diclofenac sodium releasing PLGA 80\/20 rod. J. Biomed. Mater. Res B Appl. Biomater. 89, 518\u2013526 (2009).","journal-title":"J. Biomed. Mater. Res B Appl. Biomater."},{"key":"12141_CR35","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1128\/JVI.03485-14","volume":"89","author":"K Anstett","year":"2015","unstructured":"Anstett, K., Mesplede, T., Oliveira, M., Cutillas, V. & Wainberg, M. A. Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J. Virol. 89, 4681\u20134684 (2015).","journal-title":"J. Virol."},{"key":"12141_CR36","doi-asserted-by":"publisher","first-page":"11269","DOI":"10.1128\/JVI.01881-15","volume":"89","author":"J Liang","year":"2015","unstructured":"Liang, J., Mesplede, T., Oliveira, M., Anstett, K. & Wainberg, M. A. The Combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high-level viral replication and the development of high-level drug resistance. J. Virol. 89, 11269\u201311274 (2015).","journal-title":"J. Virol."},{"key":"12141_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1185\/030079906X96425","volume":"22","author":"R Berges","year":"2006","unstructured":"Berges, R. & Bello, U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr. Med Res Opin. 22, 649\u2013655 (2006).","journal-title":"Curr. Med Res Opin."},{"key":"12141_CR38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0168-3659(00)00354-0","volume":"70","author":"JR DesNoyer","year":"2001","unstructured":"DesNoyer, J. R. & McHugh, A. J. Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems. J. Control Release 70, 285\u2013294 (2001).","journal-title":"J. Control Release"},{"key":"12141_CR39","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1002\/jps.24673","volume":"104","author":"L Solorio","year":"2015","unstructured":"Solorio, L. & Exner, A. A. Effect of the subcutaneous environment on phase-sensitive in situ-forming implant drug release, degradation, and microstructure. J. Pharm. Sci. 104, 4322\u20134328 (2015).","journal-title":"J. Pharm. Sci."},{"key":"12141_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13346-011-0054-y","volume":"2","author":"L Solorio","year":"2012","unstructured":"Solorio, L., Olear, A. M., Zhou, H., Beiswenger, A. C. & Exner, A. A. Effect of cargo properties on in situ forming implant behavior determined by noninvasive ultrasound imaging. Drug Deliv. Transl. Res 2, 45\u201355 (2012).","journal-title":"Drug Deliv. Transl. Res"},{"key":"12141_CR41","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1002\/jps.24558","volume":"104","author":"L Solorio","year":"2015","unstructured":"Solorio, L., Sundarapandiyan, D., Olear, A. & Exner, A. A. The effect of additives on the behavior of phase sensitive in situ forming implants. J. Pharm. Sci. 104, 3471\u20133480 (2015).","journal-title":"J. Pharm. Sci."},{"key":"12141_CR42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jbm.a.32724","volume":"94","author":"RB Patel","year":"2010","unstructured":"Patel, R. B., Carlson, A. N., Solorio, L. & Exner, A. A. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J. Biomed. Mater. Res. A 94, 476\u2013484 (2010).","journal-title":"J. Biomed. Mater. Res. A"},{"key":"12141_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1208\/s12249-015-0292-2","volume":"16","author":"J Guo","year":"2015","unstructured":"Guo, J. et al. The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained release carriers: in situ-forming implants. AAPS PharmSciTech. 16, 973\u2013985 (2015).","journal-title":"AAPS PharmSciTech"},{"key":"12141_CR44","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3851\/IMP2665","volume":"18","author":"JL Adams","year":"2013","unstructured":"Adams, J. L. et al. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir. Ther. 18, 1005\u20131013 (2013).","journal-title":"Antivir. Ther."},{"key":"12141_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jac\/dkh029","volume":"53","author":"RK Zeldin","year":"2004","unstructured":"Zeldin, R. K. & Petruschke, R. A. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 53, 4\u20139 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"12141_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3797\/scipharm.1507-09","volume":"84","author":"GB Bhavar","year":"2016","unstructured":"Bhavar, G. B., Pekamwar, S. S., Aher, K. B., Thorat, R. S. & Chaudhari, S. R. High-performance liquid chromatographic and high-performance thin-layer chromatographic method for the quantitative estimation of dolutegravir sodium in bulk drug and pharmaceutical dosage form. Sci. Pharm. 84, 305\u2013320 (2016).","journal-title":"Sci. Pharm."},{"key":"12141_CR47","doi-asserted-by":"crossref","unstructured":"Kovarova, M. et al. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun.\u00a0 9,\u00a04156 (2018)","DOI":"10.1038\/s41467-018-06490-w"},{"key":"12141_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/cpdd.332","volume":"6","author":"AM Buchanan","year":"2017","unstructured":"Buchanan, A. M. et al. Relative bioavailability of a dolutegravir dispersible tablet and the effects of low- and high-mineral-content water on the tablet in healthy adults. Clin. Pharm. Drug Dev. 6, 577\u2013583 (2017).","journal-title":"Clin. Pharm. Drug Dev."},{"key":"12141_CR49","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FTD.0000000000000286","volume":"38","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. A validated method for quantification of dolutegravir using ultra performance liquid chromatography coupled with UV detection. Ther. Drug Monit. 38, 327\u2013331 (2016).","journal-title":"Ther. Drug Monit."},{"key":"12141_CR50","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552\u20137557 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"12141_CR51","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.3646751","volume":"236","author":"Y Koyanagi","year":"1987","unstructured":"Koyanagi, Y. et al. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236, 819\u2013822 (1987).","journal-title":"Science"},{"key":"12141_CR52","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1128\/JVI.06157-11","volume":"86","author":"C Ochsenbauer","year":"2012","unstructured":"Ochsenbauer, C. et al. Generation of transmitted\/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 86, 2715\u20132728 (2012).","journal-title":"J. Virol."},{"key":"12141_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-88","volume":"10","author":"SR Permar","year":"2013","unstructured":"Permar, S. R. et al. Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. Retrovirology 10, 88 (2013).","journal-title":"Retrovirology"},{"key":"12141_CR54","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20090378","volume":"206","author":"JF Salazar-Gonzalez","year":"2009","unstructured":"Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted\/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206, 1273\u20131289 (2009).","journal-title":"J. Exp. Med."},{"key":"12141_CR55","doi-asserted-by":"publisher","first-page":"e1005075","DOI":"10.1371\/journal.ppat.1005075","volume":"11","author":"M Kovarova","year":"2015","unstructured":"Kovarova, M. et al. Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLoS Pathog. 11, e1005075 (2015).","journal-title":"PLoS Pathog."},{"key":"12141_CR56","doi-asserted-by":"publisher","first-page":"e1002732","DOI":"10.1371\/journal.ppat.1002732","volume":"8","author":"A Wahl","year":"2012","unstructured":"Wahl, A. et al. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog. 8, e1002732 (2012).","journal-title":"PLoS Pathog."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12141-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12141-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12141-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:17:25Z","timestamp":1721751445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-12141-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["12141"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-12141-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"assertion":[{"value":"6 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4324"}}